Dr. Joseph McNamara’s Blog

Dr. Joseph McNamara’s Blog

Joseph McNamara  //  Chiropractic Neurologist, Fellow of the American College of Functional Neurology, Nutritional Consultant, Firefighter, Father of 3, Happily married

Aug 21 / 4:36pm

Study: Astronauts as weak as 80-year-olds in space

I think the most important factor is the loss of gravity on the human body coupled with the loss of the Earths electromagnetic field. Our nervous systems have been effected by the Earths magnetic field since we were in utero and that's why people are effected by the phases of the Moon. The lack of gravity which has a huge electromagnetic component has a direct negative effect on our cells. The muscle spindles and mechanoreceptors must suffer the most which will than cause cerebellar cell atrophy and balance problems. I believe it doesn't matter how much the astronauts work out if they don't have some type of gravity their body's will deteriorate. But that's just what I believe. What do you believe?

Comments (0)

Aug 20 / 3:21am

Important Vitamin Deficiency Linked to Arterial Stiffness

Comments (0)

Aug 19 / 3:19am

Call to examine connections of swine flu experts

Julia Medew
August 13, 2010

Ads by Google

Ally Bank® Official Site

Open a Checking & Savings Account. Free Debit Card, Checks & More.

www.Ally.com

AN INDEPENDENT inquiry should look at Australia's swine flu pandemic response, including whether expert advisers had conflicts of interest involving drug companies, an infectious disease expert has said.

Professor Peter Collignon from the Australian National University said pharmaceutical companies could have influenced the government's response to the pandemic last year, especially if its advisers had worked with the industry.

He said the government should release the names of all the advisers it relied on during the pandemic, including their previous and current dealings with pharmaceutical companies to ensure transparency.

Advertisement: Story continues below

''A lot of people who make decisions indirectly are involved in pharmaceutical companies doing the research for them or whatever, so it's very difficult to separate conflicts of interests in the decision makers,'' Professor Collignon said. ''What we need is very transparent dealings. Those on the committees making decisions, we need to know who they are and the details of what contacts they have with the pharmaceutical industry.''

The call came as the World Health Organisation revealed that five of its 15 pandemic experts had received support from the industry, including for flu vaccine research.

A spokeswoman for the Federal Department of Health said she would not name the more than 50 experts who had contributed to the government's response because it was standard practice for them ''to agree to confidentiality and conflict of interest provisions''.

The spokeswoman said a thorough review of Australia's response, including lessons learned, would be made public. She would not say whether the review would be independent.

After repeated calls for the WHO to release the details of its advisers, it published a list of the 15 members of its emergency committee headed by Australian tropical diseases professor John Mackenzie - the only member named during the outbreak.

The advisers came from Africa, Asia, Europe, Latin and North America, the list posted on the WHO's website showed.

Most were scientific researchers and epidemiologists, along with a Senegalese diplomat, public health officials from Thailand and Chile and two specialists on international air travel and health.

Critics had raised concerns about potential conflicts of interest that might have helped the drugs industry influence decisions on huge orders for special vaccines against A(H1N1) flu.

The WHO has always denied those claims, underlining that it had vetted members and maintained secrecy over their identities to protect them from undue pressure during the outbreak.

Source: The Age

Ads by Google

15 Year Refinance Rates

Find the Lowest 15 Year Rate Quote No SSN Needed. Safe, Fast, & Easy!

TheEasyLoanSite.com/15year

Refinance at 3.7% FIXED

$160,000 mortgage for $547/mo. No SSN req. Get a Free Quote Now!

MortgageRefinance.LendGo.com

Top 25 Savings Accounts

Todays High Yield Savings Accounts Sort by APY, Bank Ratings, Interest

SavingsAccounts.Bankaholic.com

Comments (0)

Aug 18 / 7:27am

Lou Gehrig's Disease: New Findings Suggest Gehrig Had a Different Illness

Katie Drummond

Katie Drummond Contributor

AOL News Surge Desk

Keep an eye on your kids when they are playing sports and make sure they do pre-concussion tests.

Comments (0)

Aug 18 / 2:21am

Cymbalta Seeks Approval to Treat Chronic Pain, FDA Questions Safety - AOL Health

Federal health scientists are questioning whether the antidepressant Cymbalta is safe and effective enough to be approved for use against chronic pain.

The Food and Drug Administration on Tuesday posted its review of Eli Lilly and Co.'s application to market the drug for a range of pain ailments, including lower back pain. But FDA reviewers appeared cautious about further expanding use of a powerful psychiatric drug already used by nearly 15 million patients.

FDA reviewers raised questions about the statistical methods used to study the drug and its liver side effects.

The drug is already approved to treat depression, diabetic nerve pain and fibromyalgia.

The FDA will ask a panel of outside experts on Thursday to consider whether Cymbalta should be approved for chronic pain.

Eli Lilly has been trying to gain approval for the new indication for more than two years. The company withdrew its FDA application in November 2008 after agency evaluators questioned the method and design of some of the company's trials. The company resubmitted its application last summer with new data on Cymbalta's use against pain caused by osteoarthritis.

Three studies submitted by Lilly showed that Cymbalta lowered patient-reported pain scores significantly more than placebo after three months.

But in its review posted online, FDA scientists said Lilly's methodology still appeared "problematic." Specifically, the company included positive feedback data from patients who later dropped out of the study, possibly because of side effects to the drug. According to FDA reviewers, this practice could "potentially assign good pain scores to subjects who could not tolerate the drug."

The FDA also has concerns about widening use of a drug associated with serious liver toxicity. Cymbalta already carries a warning label about liver toxicity risks based on more than a dozen reports from patients taking the drug.

According to FDA records, use of Cymbalta has already expanded threefold - from 5 million in 2005 to 14.6 million last year - as the drug has picked up additional indications.

The agency will ask its panel of advisers to discuss the safety of further expanding the drug's use. The FDA is not required to follow the group's advice, though it often does.

Cymbalta is part of a class of drug called serotonin-norepinephrine reuptake inhibitors, which include antidepressants Effexor and Pristiq. If approved, it would be the first antidepressant cleared for chronic pain.

The drug was Eli Lilly's second best seller last year with sales of $3 billion, behind the anti-psychotic Zyprexa.

Copyright 2010 The Associated Press. The information contained in the AP news report may not be published, broadcast, rewritten or otherwise distributed without the prior written authority of The Associated Press. All active hyperlinks have been inserted by AOL.

Comments (0)

Aug 17 / 3:07am

Fight These 4 Causes of Aging

Comments (0)

Aug 16 / 3:05am

Rheumatoid Arthritis Protocol

A must read if you or any one you know has Rheumatoid arthritis.

Comments (0)

Aug 14 / 4:08am

The War Over Raw Milk Heats Up

This is not just about milk, it's about your freedom to choose what kind of foods you want to eat. Another example of the government taking away your freedom. I'm all for eating healthy but I'm also for letting you decide what you want to eat whether it's a big Mack everyday or broccoli. This is America! I think.

Comments (0)